Company profile
COGNITION THERAPEUTICS INC
NASDAQ:CGTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZERVIMESINE | phase2 | — | 9 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05531656 | phase2 | active_not_recruiting | 2023-06-28 | 2027-05-31 | Cognition Therapeutics | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease |
| NCT03507790 | phase2 | completed | 2018-10-10 | 2024-05-29 | Cognition Therapeutics | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. |
| NCT02570997 | phase1 | completed | 2015-09-01 | 2016-05-01 | Cognition Therapeutics | Ascending Dose Study of CT1812 in Healthy Volunteers |
| NCT02907567 | phase1_2 | completed | 2016-09-01 | 2017-08-24 | Cognition Therapeutics | Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease |
| NCT03716427 | phase1 | completed | 2016-11-10 | 2016-12-27 | Cognition Therapeutics | Drug Interaction Study of CT1812 in Healthy Volunteers |
FDA applications (0)
No records yet.